Open Accessibility Menu
Hide

Active Trials

Breast Cancer

A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Summary:

This randomized Phase III trial is for patients who have been diagnosed with “triple-negative” breast cancer. Triple negative means that this type of cancer does not have receptors for estrogen, progesterone, or the protein HER2 that may be found in other breast cancers. The patient must have had preoperative chemotherapy that the breast cancer has at least partially survived. The current standard of care may include no more treatment after surgery or the doctor may recommend further chemotherapy or radiation.

This study compares the usual approach (no treatment or additional treatment as recommended by your doctor) and one year of the experimental drug MK-3475 (also called pembrolizumab). This study will allow researchers to know whether treatment with MK-3475 is better, the same, or worse than the usual approach alone.

For More Information: https://clinicaltrials.gov/ct2/show/NCT02954874?term=s1418&draw=2&rank=1

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/ Trastuzumab/ Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Summary:

This Phase III trial is for patients who have HER2-positive metastatic breast cancer. The usual approach to this cancer is chemotherapy combined with trastuzumab and pertuzumab. This trial compares the usual treatment and placebo versus the usual treatment and atezolizumab. Atezolizumab is already approved by the FDA for use in non-small cell lung and urinary cancer. The use in this study is considered experimental. This trial is double-blinded, meaning that neither the patient nor the health care team will know which treatment you will be receiving.

For More Information: https://clinicaltrials.gov/ct2/show/NCT03199885?term=br004&draw=2&rank=2

Lung Cancer

Lung Cancer In Older Adults: Treatment Toxicity Through the Patient’s Lens

Summary:

This study is for patients who are 65 years or older, have lung cancer and will be starting a new treatment. The purpose of this study is to learn more about how older adults tolerate lung cancer treatment and how treatment affects their daily lives.

For More Information: http://cancer.ucsf.edu/support/older-adult/research

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

Summary:

This screening study is for patients who have been diagnosed with non-small cell lung cancer. The patient will be asked to submit their tumor sample to test for specific genes and proteins. Based on the test results, the patient may be assigned to a treatment substudy. This will take place if and when the patient progresses.

For More Information: https://clinicaltrials.gov/ct2/show/NCT03851445?term=lungmap&draw=2&rank=1

Colorectal Cancer

GO: Gut Microbiome and Oral Fluoropyrimidine Study in Patients with Colorectal Cancer

Summary:

This purpose of this study is to investigate the alterations in the gut microbiome that occur during the course of treatment for colorectal cancer (CRC).

For More Information: https://clinicaltrials.ucsf.edu/trial/NCT04054908

Related Locations